Jefferies reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), and raised the price target to $22.00 (from $20.00), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE